Cellectis

    [td_text_with_title custom_title=”Company description”]Cellectis is a preclinical stage biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in genome engineering – based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology – to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS).

    TALEN® is a registered trademark owned by Cellectis Group.[/td_text_with_title]

    Drugs

    Posts not found

    [td_text_with_title custom_title=”Latest post”]

    Posts not found

    [/td_text_with_title][td_text_with_title custom_title=”From Wikipedia”]

    Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy.[1] It has offices in Paris and New York City.

    Cellectis was founded by André Choulika in 1999.[2] It built up a successful business based on the use of meganucleases in genome engineering. Cellectis went public in 2007, and raised €21 million in a stock offering on EuroNext. In 2010 it acquired Cyto Pulse, which had developed a new electroporation technology,[3] and in 2011 it paid €26 million for Cellartis, a Swedish biotechnology company.[2] The company employed nearly 300 people.[2]

    With the advent of the CRISPR (clustered regularly interspaced short palindromic repeat) genome editing technique, the Cellectis meganuclease technology became uneconomic, and by 2013 the company was close to bankruptcy. It restructured, closed laboratories and reduced staff, and shifted research emphasis toward CAR-T technologies for cancer immunotherapy. In 2014 it reached financing deals with Servier and Pfizer.[2]

    In March 2015 the company raised US$228 million through a stock offering on NASDAQ. The shares fell by 15% in the first week of trading.[4]

    References

    1. ^ Bryce Elder, Arash Massoud, Andrew Ward, David Crow (28 May 2015). Biotech Cellectis in takeover talks with Pfizer. Financial Times. Accessed March 2016. (subscription required).
    2. ^ a b c d Philip Hemme (15 July 2015). "How Servier saved Cellectis, the French CAR-T Miracle". Labiotech.eu. Retrieved 16 March 2016. 
    3. ^ "Genetic Engineering & Biotechnology News - Biotech from Bench to Business". Genengnews.com. 8 November 2013. Archived from the original on 22 March 2016. Retrieved 16 March 2016. 
    4. ^ "US IPO Weekly Recap: SolarEdge shines while other IPOs fall flat". NASDAQ.com. 27 March 2015. Retrieved 18 September 2017. 
    source: https://en.wikipedia.org/wiki/Cellectis[/td_text_with_title]